Lycia Therapeutics logo

Head of Investor Relations

Lycia Therapeutics

South San Francisco, CAHybridPosted 1 day ago$225,000 - $375,000/year
Full TimeDirector & AboveCorporate FunctionsBiotechnology
Original posting ↗

Summary

Lycia is hiring a Head of Investor Relations to build the function following the company's initial public offering. Title will reflect the experience of the person hired. The role reports to the Chief Financial Officer and works closely with the Chief Executive Officer and the executive team. This leader will manage Lycia's relationships with investors, sell-side analysts and banking partners, and will shape how the company's science, clinical progress and financial position are communicated to the market. It is a hands-on role for someone who wants to build a public company IR program from the ground up.

Job description

Key responsibilities

  • Build and lead Lycia's investor relations strategy, annual IR activities and investor targeting program to develop a high-quality, long-term institutional shareholder base, and monitor shareholder composition, trading activity and investor sentiment.
  • Own the equity story and investor narratives and adapt the investment case and corporate presentation for different investor audiences without compromising scientific precision.
  • Lead planning process for clinical data releases, including advising on disclosure timing, preparing press releases and presentation materials, ensuring key opinion leader participation and post-release investor follow-up, in coordination with clinical, regulatory and legal teams.
  • Plan and execute investor and disease-specific conferences, non-deal roadshows, investor and analyst events and key opinion leader events, and prepare management for these events.
  • Lead communications for quarterly reporting incorporating clinical, regulatory, financing and corporate milestones, including press releases, key messages and investor Q&A, partnering with Legal and Finance on disclosure controls and review of external materials.
  • Partner with the Chief Business Officer on corporate communications, owning investor-facing content on the website, press releases and corporate social media, and contributing to broader media, partner and brand messaging so that narrative and positioning stay consistent across audiences.
  • Build relationships with sell-side analysts, including in-depth review of models and leading strategic coverage expansion beyond current analysts.
  • Lead competitive intelligence and synthesize insight from investors, analysts, key opinion leaders and other market participants to sharpen positioning, test assumptions and inform program strategy, consistent with Lycia's scientific and compliance processes. Apply AI and digital tools to literature and competitor synthesis, landscape monitoring, message testing and investor meeting tracking. Proactively bring insights to management.

Qualifications

  • 10 or more years of experience in biotechnology investor relations, capital markets, equity research, investment banking or an IR advisory firm, including direct experience leading IR at a public company or advising public company management teams.
  • Track record of supporting clinical readouts, financings and other market-moving events.
  • Established relationships with healthcare-focused institutional investors, sell-side analysts and banks.
  • Working knowledge of SEC disclosure requirements, Regulation FD and public company reporting processes.
  • Scientific fluency sufficient to explain a novel therapeutic platform and clinical data credibly to specialist investors.
  • Strong writing, judgment and executive presence, and comfort operating as a hands-on, one-person function working closely with the management team.
  • Bachelor's degree required. An advanced degree in the life sciences or business is preferred.

Requirements

  • 10 or more years of experience in biotechnology investor relations, capital markets, equity research, investment banking or an IR advisory firm
  • Direct experience leading IR at a public company or advising public company management teams
  • Track record of supporting clinical readouts, financings and other market-moving events
  • Established relationships with healthcare-focused institutional investors, sell-side analysts and banks
  • Working knowledge of SEC disclosure requirements, Regulation FD and public company reporting processes
  • Scientific fluency sufficient to explain a novel therapeutic platform and clinical data credibly to specialist investors
  • Strong writing, judgment and executive presence
  • Comfort operating as a hands-on, one-person function working closely with the management team
  • Bachelor's degree required
  • Advanced degree in the life sciences or business preferred

Benefits

  • Annual Performance Bonus
  • Equity
  • Benefits Program

Company overview

Lycia Therapeutics is a biotechnology company pioneering a novel approach to treating previously undruggable diseases through extracellular protein degradation. Founded in 2020 and headquartered in South San Francisco, California, the company is developing innovative LYTAC (Lysosome-Targeting Chimera) therapeutics designed to bind and eliminate disease-causing extracellular proteins by directing them into cells for degradation via the lysosome. The company's platform technology specifically targets proteins outside the cell, addressing a significant gap in current therapeutic approaches. Lycia initially focuses on autoimmune and inflammatory diseases, with lead programs targeting conditions like allergic asthma, chronic urticaria, and Graves' disease. The company has raised substantial funding, including a $106.6 million Series C round in 2024, demonstrating strong investor confidence in their technology platform. Lycia's modular therapeutics can be customized for various pathogenic proteins, offering new hope for patients with limited treatment options.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.